ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Letrozole

Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.

Drug pageLetrozole: every studyMany companies study it; this page follows only the 38 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 10, 200138 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only280 open or runningphase 4since Apr 10, 2001Apr 10, 2001none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Egymedicalpediaits history only21 open or runningphase 1since Apr 9, 2024Apr 9, 2024none ahead
Hikma Pharmaceuticalsits history only20 open or runningphase 1since Jun 3, 2011Jun 3, 2011none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Rovi Pharmaceuticals Laboratoriesits history only10 open or runningphase 1since Jan 8, 2018Jan 8, 2018none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 3since Jan 24, 2008Jan 24, 2008none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2008First studies: 2 phase 1 studies in HealthyFirst studyNCT00648154, NCT00648063

TargetBeta

CYP19A1 →read by rule
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule

Studies

All 2 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00648154Healthy · United States1CompletedDec 200524
NCT00648063Healthy · United States1CompletedDec 200524

How it is read

Names in the registry

  • “Letrozole”, 40 entries
  • “letrozole”, 6 entries
  • “Letrozole Tablets 2.5 mg”, 2 entries
  • “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
  • “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.